---
title: "Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Cost-effectiveness evidence"
description: "Formulary evidence on Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Cost-effectiveness evidence. Topics: Cretostimogene grenadenorepvec in published economic models of the indication, Company statements on pricing of cretostimogene grenadenorepvec, Budget impact of nadofaragene firadenovec in a United States health plan, Cost-effectiveness of radical cystectomy and bladder-sparing treatments for BCG-unresponsive carcinoma in situ, and 7 further topics. 12 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics/cost-effectiveness"
published: "2026-11-18T10:43:03-05:00"
modified: "2026-11-18T10:43:03-05:00"
---

# Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Cost-effectiveness evidence

<a id="heading-4.1"></a>

## 4.1 Modeling Overview

<a id="topic-4.1-1"></a>

### Summary

No budget impact model, cost-effectiveness analysis, or health technology assessment of cretostimogene grenadenorepvec was found, and CG Oncology has announced no price. Its Form 10-K states that the “pricing of existing drugs may limit the amount we will be able to charge for our products”. Published U.S. economic evaluations in BCG-unresponsive high-risk NMIBC address the approved comparators. A Ferring-funded budget impact model of nadofaragene firadenovec estimated a budget impact of $0.0010 to $0.0084 per member per month over 3 years in a plan of one million members for CIS ± Ta/T1 disease, and $0.0064 to $0.0548 when papillary-only disease was included; the authors note that cretostimogene was “under investigation in ongoing trials for similar indications” and was not modeled. A 5-year Medicare Markov model found gemcitabine/docetaxel the most cost-effective option for a patient willing to try one line of therapy or proceed directly to radical cystectomy, radical cystectomy for a patient open to two lines of therapy or upfront radical cystectomy, and pembrolizumab for a patient willing to try up to 2 lines of FDA-approved therapy before radical cystectomy. A Johnson & Johnson-funded 15-month cost-per-responder model estimated that 43.5% of patients treated with TAR-200 achieved and sustained a complete response for at least 12 months, against 18.8% to 26.8% for pembrolizumab, nadofaragene firadenovec, and nogapendekin alfa inbakicept plus BCG without reinduction, and 10.1% for valrubicin. The 2020 ICER review estimated $151,000 per QALY gained for nadofaragene firadenovec and $114,000 for pembrolizumab against a hypothetical comparator with a 0% complete response rate, and a health-benefit price benchmark of $158,600 to $262,000 per year for nadofaragene firadenovec. Two other models found pembrolizumab not cost-effective at its price at the time, one estimating that a 5.4% price reduction would make it cost-effective, and a further analysis found nadofaragene firadenovec cost-effective against radical cystectomy at $10,014 per QALY at a willingness-to-pay threshold of $100,000. ImmunityBio reported preliminary results of a health economic analysis, based on complete response rates from an indirect treatment comparison, in which nogapendekin alfa inbakicept plus BCG had a lower cost per sustained complete responder than TAR-200.

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm); [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599); [Myers et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13454959/); [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037); [Beinfeld et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391138/); [Wymer et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33347775/); [Joshi et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36529422/); [D'Andrea et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39550339/); [ImmunityBio ISPOR 2026 health economic analysis press release (2026)](https://immunitybio.gcs-web.com/node/11506)

<a id="topic-4.1-2"></a>

### Budget impact model, cost-effectiveness analysis, or health technology assessment of cretostimogene grenadenorepvec

No evidence found.

<a id="topic-4.1-3"></a>

### Cretostimogene grenadenorepvec in published economic models of the indication

> “In recent years, the FDA has approved several new agents for high-risk, BCG-unresponsive NMIBC with CIS ± Ta/T1, including pembrolizumab, nadofaragene firadenovec, nogapendekin alfa inbakicept-pmln + BCG, and TAR-200, while additional therapies such as cretostimogene grenadenorepvec are under investigation in ongoing trials for similar indications as of the drafting of this manuscript.”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-4.1-4"></a>

### Company statements on pricing of cretostimogene grenadenorepvec

> “Even if we are successful in demonstrating improved efficacy or improved convenience of administration with our products, pricing of existing drugs may limit the amount we will be able to charge for our products.”

Source: [CG Oncology Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1991792/000119312526079498/ck0001991792-20251231.htm)

<a id="topic-4.1-5"></a>

### Budget impact of nadofaragene firadenovec in a United States health plan

> “To estimate the budget impact of adopting nadofaragene firadenovec for the treatment of adults with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ with or without papillary tumors (CIS ± Ta/T1) from a US third-party payer’s perspective.”
> “In the base-case, the estimated per-member-per-month (PMPM) budget impact of adopting nadofaragene firadenovec ranged from $0.0010 in Year 1 to $0.0084 in Year 3.”
> “Funding for this study was provided by Ferring Pharmaceuticals.”

Source: [Yang et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2630599)

<a id="topic-4.1-6"></a>

### Cost-effectiveness of radical cystectomy and bladder-sparing treatments for BCG-unresponsive carcinoma in situ

> “We developed a Markov decision analytic model to assess five treatments: RC, nadofaragene, nogapendekin, pembrolizumab, and gemcitabine/docetaxel.”
> “For index patient 1, who is willing to try one line of therapy or proceed directly to RC, gemcitabine/docetaxel was the most cost-effective option. For index patient 2, open to two lines of therapy or upfront RC, RC was the most cost-effective. For index patient 3, willing to try up to 2 lines of FDA-approved therapy (pembrolizumab, nadofaragene, or nogapendekin) before RC, pembrolizumab was the most cost-effective option.”
> “Current pricing of bladder-sparing treatments poses significant financial barriers, highlighting the need for better treatment selection tools and more equitable pricing.”

Source: [Myers et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13454959/)

<a id="topic-4.1-7"></a>

### Cost per responder of TAR-200 versus FDA-approved comparators

> “A 15-month cost-per-responder model was developed from a Medicare payer perspective (2025 USD).”
> “At 15 months, the proportion of patients achieving and sustaining CR for ≥12 months was 43.5% for TAR-200, 18.8% for pembrolizumab, 21.9% for NF, 26.8% for NAI+BCG (36.6% with reinduction), and 10.1% for valrubicin.”
> “This study was funded by Johnson & Johnson.”

Source: [Williams et al. (2026)](https://www.tandfonline.com/doi/full/10.1080/13696998.2026.2651037)

<a id="topic-4.1-8"></a>

### ICER review of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab

> “The Institute for Clinical and Economic Review (ICER) conducted a systematic literature review and cost-effectiveness analysis to evaluate the health and economic outcomes of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive NMIBC.”
> “The base-case cost-effectiveness, with each drug compared with the hypothetical comparator with a 0% CR at 3 months, were $151,000 per QALY gained for nadofaragene firadenovec, $382,000 per QALY gained for oportuzumab monatox, and $114,000 per QALY gained for pembrolizumab.”
> “The HBPB for nadofaragene firadenovec ranged from $158,600 to $262,000 per year.”

Source: [Beinfeld et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391138/)

> “January 15, 2021 Update: A data entry error affected model results regarding nadofaragene firadenovec when used in the Ta/T1 population. Results have been corrected in this update, and include a revised Health-Benefit Price Benchmark (HBPB) range for nadofaragene firadenovec.”
> “As such, this ICER report should be considered no longer current with respect to oportuzumab monatox.”

Source: [ICER Bladder Cancer Final Evidence Report (2020)](https://icer.org/wp-content/uploads/2020/08/ICER_Bladder_Cancer_Final_Report_07292022.pdf)

<a id="topic-4.1-9"></a>

### Cost-effectiveness of nadofaragene firadenovec and pembrolizumab versus a hypothetical alternative

> “Nadofaragene firadenovec, at a placeholder price 10% higher than the price of pembrolizumab, had an incremental cost-effectiveness ratio of $263 000 and $145 000 per QALY gained in CIS and non-CIS populations, respectively. Pembrolizumab had an incremental cost-effectiveness ratio of $168 000 per QALY gained for CIS.”
> “The cost-effectiveness of nadofaragene firadenovec will depend upon its price.”

Source: [Joshi et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36529422/)

<a id="topic-4.1-10"></a>

### Cost-effectiveness of pembrolizumab versus salvage intravesical chemotherapy and radical cystectomy

> “At its current price, pembrolizumab is not cost-effective for bacillus Calmette-Guérin-unresponsive carcinoma in situ relative to radical cystectomy or salvage intravesical chemotherapy.”

Source: [Wymer et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33347775/)

<a id="topic-4.1-11"></a>

### Cost-effectiveness of approved bladder-sparing agents in a systematic review and Markov model

> “Compared with using radical cystectomy to treat patients failing BCG therapy, at a willingness-to-pay threshold of 100 000 USD, nadofaragene firadenovec was cost effective, with an incremental cost-effectiveness ratio (ICER) of 10 014 USD per quality-adjusted life year (QALY), while nogapendekin alfa inbakicept was less cost effective than nadofaragene firadenovec (ICER of 44 602 USD per QALY). Pembrolizumab, which dominated, was both less costly and more effective than the other strategies.”

Source: [D'Andrea et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/39550339/)

<a id="topic-4.1-12"></a>

### Cost-effectiveness of salvage treatments in a German payer setting

> “Considering a WTP of <€50 000/QALY, gemcitabine/docetaxel and HIVEC are highly cost-effective therapeutic options in BCG-refractory NMIBC, while RC remains the cheapest option. At its current price, pembrolizumab would only be cost-effective assuming a price reduction of at least 70%.”

Source: [Rieger et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38491799/)

<a id="topic-4.1-13"></a>

### Manufacturer-reported cost-consequence analysis of nogapendekin alfa inbakicept plus BCG versus TAR-200

> “ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced preliminary results from a new health economic analysis demonstrating that ANKTIVA® (nogapendekin alfa inbakicept-pmln; NAI) plus Bacillus Calmette–Guérin (BCG) achieved a lower cost per sustained complete responder compared to TAR-200 in patients with BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ ± papillary disease (NMIBC CIS).”

Source: [ImmunityBio ISPOR 2026 health economic analysis press release (2026)](https://immunitybio.gcs-web.com/node/11506)

## Related pages
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Terms and abbreviations](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/terms-and-abbreviations.md)
- [Cretostimogene grenadenorepvec (CG0070): BCG-unresponsive high-risk non-muscle-invasive bladder cancer](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/executive-summary.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Product information and disease description](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/product-information-and-disease-description.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Clinical evidence](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/clinical-evidence.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: Economic information and modeling report](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/economics.md)
- [Cretostimogene grenadenorepvec (CG0070) in BCG-unresponsive high-risk non-muscle-invasive bladder cancer: References](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references) · [Markdown](https://www.evicenter.com/drugs/cretostimogene-grenadenorepvec--bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer/references.md)
